新型抗凝剂与抗血小板药物联合使用。

New anticoagulants in combination with antiplatelet agents.

作者信息

Johansen Henriette, Rutherford Ole-Christian Walter, Aamodt Anne Hege, Russell David, Atar Dan, Ghanima Waleed

机构信息

Nevrologisk avdeling Klinikk for kirurgi og nevrofag Oslo universitetssykehus, Rikshospitalet.

Medisinsk avdeling Sykehuset Østfold.

出版信息

Tidsskr Nor Laegeforen. 2016 Oct 11;136(18):1543-1546. doi: 10.4045/tidsskr.15.1356. eCollection 2016 Oct.

DOI:10.4045/tidsskr.15.1356

PMID:27731598

Abstract

The use of new, direct anticoagulants is increasing. Data from both controlled trials and clinical practice have shown that these drugs are as efficacious and safe as warfarin for deep vein thrombosis and pulmonary embolism, and as stroke prophylaxis for patients with atrial fibrillation. But what if platelet inhibition is also indicated? In the following, the combination of antiplatelets and the new anticoagulants is discussed for various indications.

摘要

新型直接抗凝剂的使用正在增加。对照试验和临床实践的数据均表明，这些药物在治疗深静脉血栓形成和肺栓塞方面与华法林一样有效且安全，在预防心房颤动患者中风方面也是如此。但是，如果也需要抑制血小板呢？以下将讨论抗血小板药物与新型抗凝剂在各种适应症中的联合应用。